BioSpace News Archive

Dipti Talaulikar, MBBS, PhD, a clinician and researcher with extensive involvement in hematology, has joined George Clinical, a global scientifically-backed clinical research organization, as a member of the organization’s scientific leadership.

For decades, physicians have been taught—and have told patients—that antimicrobials do not help viral diseases.

The Medical Device Innovation Consortium (MDIC) today announced that its board of directors has elected Jijo James, Chief Medical Officer of Johnson & Johnson Medical Devices Companies, as the new chair-elect of the MDIC board.

Therapy Brands has announced Dr. Jessica Kasirsky as their new Chief Medical Officer and Vice President of Regulatory Affairs.

- Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), announced today that RADICAVA ® (edaravone), an infusion treatment for amyotrophic lateral sclerosis (ALS), is now reimbursed by Veterans Affairs Canada (VAC) and Indigenous Services Canada via the Non-Insured Health Benefits (NIHB)

Food allergy patient registry informs groundbreaking research, with patient-reported data on numbers and reasons for reactions

Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced that the interim results from the FLASH study have been accepted for presentation in a late-breaking clinical science session at TCT Connect. The FLASH study is evaluating the safety and effectiveness of the FlowTriever

ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced the submission of a Biologics License Application (B

Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its transaction to acquire Forbius for their TGF-beta program, including its lead investigational asset AVID200, currently in Phase 1 for oncology and fibrosis. “We are pleased to complete the transaction with Forbius and add their TGF-beta program to

BioLife Sciences Inc. (OTC Markets: BLFE) announced today that it has entered into an agreement with BeMotion Inc. to become a licensed distributor of the company’s innovative technology products. Under the terms of the agreement, BioLife Sciences will gain the right to distribute products by BeMotion which include non-contact human temperature screening technology, ultraviolet sterilization, and touchless vending/marketp